Apollomics announces preliminary data on vebreltinib

Apollomics announced today positive preliminary clinical data for the cohort of patients with non-CNS MET fusion solid tumors from the Phase 2 SPARTA trial of vebreltinib. Key preliminary clinical data highlights from 14 patients by RECIST v1.1: 43% objective response rate: Six confirmed responses by RECIST 1.1 criteria, out of 14 evaluable patients including one complete response in third-line metastatic NSCLC and five partial responses. Median overall survival was 12.4 months and median progression free survival was 4.5 months. 5.6 months median duration of response and 3.7 months median time to response. The longest duration of response is 18 months, with that patient currently continuing treatment.